Topical Collection "Immuno-Metabolic Crosstalk in Oncogenesis"

A topical collection in Cells (ISSN 2073-4409). This collection belongs to the section "Cellular Immunology".

Editor

Prof. Aksam J. Merched
E-Mail Website
Collection Editor
Department of Health Sciences and Bordeaux Institute of Oncology (INSERM U1312), University of Bordeaux, 146 rue Léo Saignat, CEDEX, 33076 Bordeaux, France
Interests: metabolism; inflammation; immunosuppression; cancers; lipids; liver

Topical Collection Information

Dear colleagues,

Altered cellular metabolism and immunosuppression in the tumor microenvironment became emerging hallmarks of cancer. Oncometabolites are needed to sustain tumor cell survival, growth, and proliferation by fulfilling the energetic needs and providing the raw materials and signaling molecules for many oncogenic pathways. Some are capable of driving immune cell polarization toward immunosuppressive and cancer-tolerant isotypes. The main focus of this Topical Collection is the crosstalk between these two hallmarks in the context of oncogenesis. Decoding this subtle crosstalk at the molecular and cellular levels is a prerequisite for the discovery of more effective combinatory therapeutic approaches targeting immuno-metabolism of cancers.

I am seeking all topics relevant to metabolic defect, adaptation, nutritional addiction of cancer cells, and modulation of tumor-targeted immune responses.

I am looking forward to receiving your contribution.

Prof. Aksam J. Merched
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • immune resolution
  • immunosuppression
  • immunoediting
  • immunotherapy
  • mitochondria
  • metabolism
  • oncometabolites
  • nutritional dependence
  • epigenetics

Published Papers (6 papers)

2022

Jump to: 2021

Article
CLL-Derived Extracellular Vesicles Impair T-Cell Activation and Foster T-Cell Exhaustion via Multiple Immunological Checkpoints
Cells 2022, 11(14), 2176; https://doi.org/10.3390/cells11142176 - 12 Jul 2022
Cited by 1 | Viewed by 1117
Abstract
Background: Chronic lymphocytic leukemia (CLL) is characterized by the clonal expansion of malignant B-cells and multiple immune defects. This leads, among others, to severe infectious complications and inefficient immune surveillance. T-cell deficiencies in CLL include enhanced immune(-metabolic) exhaustion, impaired activation and cytokine production, [...] Read more.
Background: Chronic lymphocytic leukemia (CLL) is characterized by the clonal expansion of malignant B-cells and multiple immune defects. This leads, among others, to severe infectious complications and inefficient immune surveillance. T-cell deficiencies in CLL include enhanced immune(-metabolic) exhaustion, impaired activation and cytokine production, and immunological synapse malformation. Several studies have meanwhile reported CLL-cell–T-cell interactions that culminate in T-cell dysfunction. However, the complex entirety of their interplay is incompletely understood. Here, we focused on the impact of CLL cell-derived vesicles (EVs), which are known to exert immunoregulatory effects, on T-cell function. Methods: We characterized EVs secreted by CLL-cells and determined their influence on T-cells in terms of survival, activation, (metabolic) fitness, and function. Results: We found that CLL-EVs hamper T-cell viability, proliferation, activation, and metabolism while fostering their exhaustion and formation of regulatory T-cell subsets. A detailed analysis of the CLL-EV cargo revealed an abundance of immunological checkpoints (ICs) that could explain the detected T-cell dysregulations. Conclusions: The identification of a variety of ICs loaded on CLL-EVs may account for T-cell defects in CLL patients and could represent a barrier for immunotherapies such as IC blockade or adoptive T-cell transfer. Our findings could pave way for improving antitumor immunity by simultaneously targeting EV formation or multiple ICs. Full article
Show Figures

Graphical abstract

Review
Influence of the Metabolism on Myeloid Cell Functions in Cancers: Clinical Perspectives
Cells 2022, 11(3), 554; https://doi.org/10.3390/cells11030554 - 05 Feb 2022
Viewed by 735
Abstract
Tumor metabolism plays a crucial role in sustaining tumorigenesis. There have been increasing reports regarding the role of tumor metabolism in the control of immune cell functions, generating a potent immunosuppressive contexture that can lead to immune escape. The metabolic reprogramming of tumor [...] Read more.
Tumor metabolism plays a crucial role in sustaining tumorigenesis. There have been increasing reports regarding the role of tumor metabolism in the control of immune cell functions, generating a potent immunosuppressive contexture that can lead to immune escape. The metabolic reprogramming of tumor cells and the immune escape are two major hallmarks of cancer, with several instances of crosstalk between them. In this paper, we review the effects of tumor metabolism on immune cells, focusing on myeloid cells due to their important role in tumorigenesis and immunosuppression from the early stages of the disease. We also discuss ways to target this specific crosstalk in cancer patients. Full article
Show Figures

Figure 1

2021

Jump to: 2022

Review
Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment
Cells 2021, 10(12), 3529; https://doi.org/10.3390/cells10123529 - 14 Dec 2021
Cited by 3 | Viewed by 1333
Abstract
Glioblastoma (GBM) is the most aggressive brain tumor in adults and is characterized by an immunosuppressive microenvironment. Different factors shaping this tumor microenvironment (TME) regulate tumor initiation, progression, and treatment response. Genetic alterations and metabolism pathways are two main elements that influence tumor [...] Read more.
Glioblastoma (GBM) is the most aggressive brain tumor in adults and is characterized by an immunosuppressive microenvironment. Different factors shaping this tumor microenvironment (TME) regulate tumor initiation, progression, and treatment response. Genetic alterations and metabolism pathways are two main elements that influence tumor immune cells and TME. In this manuscript, we review how both factors can contribute to an immunosuppressive state and overview the strategies being tested. Full article
Show Figures

Figure 1

Review
Immuno-Metabolic Modulation of Liver Oncogenesis by the Tryptophan Metabolism
Cells 2021, 10(12), 3469; https://doi.org/10.3390/cells10123469 - 09 Dec 2021
Cited by 1 | Viewed by 1064
Abstract
Metabolic rewiring in tumor cells is a major hallmark of oncogenesis. Some of the oncometabolites drive suppressive and tolerogenic signals from the immune system, which becomes complicit to the advent and the survival of neoplasia. Tryptophan (TRP) catabolism through the kynurenine (KYN) pathway [...] Read more.
Metabolic rewiring in tumor cells is a major hallmark of oncogenesis. Some of the oncometabolites drive suppressive and tolerogenic signals from the immune system, which becomes complicit to the advent and the survival of neoplasia. Tryptophan (TRP) catabolism through the kynurenine (KYN) pathway was reported to play immunosuppressive actions across many types of cancer. Extensive debate of whether the culprit of immunosuppression was the depletion of TRP or rather KYN accumulation in the tumor microenvironment has been ongoing for years. Results from clinical trials assessing the benefit of inhibiting key limiting enzymes of this pathway such as indoleamine 2,3-dioxygenase (IDO1) or tryptophan 2,3-dioxygenase (TDO2) failed to meet the expectations. Bearing in mind the complexity of the tumoral terrain and the existence of different cancers with IDO1/TDO2 expressing and non-expressing tumoral cells, here we present a comprehensive analysis of the TRP global metabolic hub and the driving potential of the process of oncogenesis with the main focus on liver cancers. Full article
Show Figures

Figure 1

Review
The Metabolic Control of Myeloid Cells in the Tumor Microenvironment
Cells 2021, 10(11), 2960; https://doi.org/10.3390/cells10112960 - 30 Oct 2021
Cited by 1 | Viewed by 1329
Abstract
Myeloid cells are a key determinant of tumor progression and patient outcomes in a range of cancers and are therefore being actively pursued as targets of new immunotherapies. The recent use of high-dimensional single-cell approaches, e.g., mass cytometry and single-cell RNA-sequencing (scRNA-seq) has [...] Read more.
Myeloid cells are a key determinant of tumor progression and patient outcomes in a range of cancers and are therefore being actively pursued as targets of new immunotherapies. The recent use of high-dimensional single-cell approaches, e.g., mass cytometry and single-cell RNA-sequencing (scRNA-seq) has reinforced the predominance of myeloid cells in the tumor microenvironment and uncovered their phenotypic diversity in different cancers. The cancerous metabolic environment has emerged as a critical modulator of myeloid cell functions in anti-tumor immunity versus immune suppression and immune evasion. Here, we discuss mechanisms of immune-metabolic crosstalk in tumorigenesis, with a particular focus on the tumor-associated myeloid cell’s metabolic programs. We highlight the impact of several metabolic pathways on the pro-tumoral functions of tumor-associated macrophages and myeloid-derived suppressor cells and discuss the potential myeloid cell metabolic checkpoints for cancer immunotherapy, either as monotherapies or in combination with other immunotherapies. Full article
Show Figures

Figure 1

Communication
Alteration of Tissue Marking Dyes Depends on Used Chromogen during Immunohistochemistry
Cells 2021, 10(4), 835; https://doi.org/10.3390/cells10040835 - 08 Apr 2021
Viewed by 775
Abstract
Pathological biopsy protocols require tissue marking dye (TMD) for orientation. In some cases (e.g., close margin), additional immunohistochemical analyses can be necessary. Therefore, the correlation between the applied TMD during macroscopy and the examined TMD during microscopy is crucial for the correct orientation, [...] Read more.
Pathological biopsy protocols require tissue marking dye (TMD) for orientation. In some cases (e.g., close margin), additional immunohistochemical analyses can be necessary. Therefore, the correlation between the applied TMD during macroscopy and the examined TMD during microscopy is crucial for the correct orientation, the residual tumour status and the subsequent therapeutic regime. In this context, our group observed colour changes during routine immunohistochemistry. Tissue specimens were marked with various TMD and processed by two different methods. TMD (blue, red, black, yellow and green) obtained from three different providers (A, B and C, and Whiteout/Tipp-Ex®) were used. Immunohistochemistry was performed manually via stepwise omission of reagents to identify the colour changing mechanism. Blue colour from provider A changed during immunohistochemistry into black, when 3,3′-Diaminobenzidine-tetrahydrochloride-dihydrate (DAB) and H2O2 was applied as an immunoperoxidase-based terminal colour signal. No other applied reagents, nor tissue texture or processing showed any influence on the colour. The remaining colours from provider A and the other colours did not show any changes during immunohistochemistry. Our results demonstrate an interesting and important pitfall in routine immunohistochemistry-based diagnostics that pathologists should be aware of. Furthermore, the chemical rationale behind the observed misleading colour change is discussed. Full article
Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: Gliomas: relationship between metabolism and microenvironment
Authors: Ainhoa Hernández; Ana M. Muñoz-Mármol; Cristina Carrato; Marta Domenech; Carmen Balana
Affiliation: 1Institut Catala d’Oncologia (ICO) Badalona, Badalona Applied Research Group in Oncology (B- ARGO Group), Institut Investigació Germans Trias i Pujol (IGTP), Badalona, Spain 2Pathology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Abstract: /

Title: Tumour metabolism in myeloid-driven immunosuppression
Authors: Thomas Boyer1; Céline Blaye1,2; Nicolas Larmonier1,3; Charlotte Domblides1,4
Affiliation: 1. CNRS UMR5164, ImmunoConcEpT, Bordeaux, France 2. Department of Medical Oncology, Bergonie Institute, Bordeaux, France 3. Department of Life and Medical Sciences, University of Bordeaux, Bordeaux, France 4. Department of Medical Oncology, Hôpital Saint-André, University Hospital Bordeaux, France
Abstract: Tumour metabolism plays a crucial role in sustaining tumorigenesis. Increasing reports highlight the role of tumour metabolism in the control of immune cell functions, generating a potent immunosuppressive contexture leading to immune escape. The metabolic reprogramming of tumour cells and the immune escape are two major hallmarks of cancer, with several cross talks between them. Here, we propose to review the effect of tumour metabolism on immune cells focusing on myeloid-cells, due to their important role in tumorigenesis and immunosuppression, from the early stages of the disease. We will also discuss about ways to target this specific crosstalk in cancer patients.

Title: Immuno-metabolic modulation of liver oncogenesis by the tryptophan
Authors: Véronique Trézéguet-Busquet; Hala Fatrouni; Aksam Merched
Affiliation: Bordeaux University and Inserm U 1035, Biotherapy of Genetic, Inflammatory Diseases and Cancer (BMGIC), MiRCade Team; Bordeaux, France.
Abstract: Metabolic rewiring in tumor cells is a major hallmark of oncogenesis. Some of the oncometabolites drive suppressive and tolerogenic signals from the immune system, which becomes complicit to the advent and the survival of neoplasia. Tryptophan catabolism through the kynurenin (Kyn) pathway was reported to play immunosuppressive actions across many types of cancer. Extensive debate of whether the culprit of immunosuppression was the depletion of Trp or rather Kyn accumulation in the tumor microenvironment has been ongoing for years. Results from clinical trials assessing the benefit of inhibiting key limiting enzymes of this pathway such as indoleamine 2,3-dioxygenase (IDO1) failed to meet the expectations. Bearing in mind the complexity of the tumoral terrain and the existence of different cancers with IDO1/TDO expressing and non-expressing tumoral cells, here we present a comprehensive analysis of the trp global metabolic hub and the driving potential of the process of oncogenesis with main focus on liver cancers.

Title: Metabolic control of myeloid cells in the tumor microenvironment
Authors: Eloise Ramel; Sebastian Lillo; Boutaina Daher; Marina Fioleau; Thomas Daubon; Maya Saleh
Affiliation: Université Bordeaux
Abstract: Myeloid cells are key determinants of tumor progression and patient outcome in several cancers and are being actively pursued as targets of new immunotherapies. The recent use of high-dimensional single cell approaches e. g. mass cytometry and single-cell RNA sequencing [scRNAseq]) has reinforced the predominance of myeloid cells in the tumor microenvironment and uncovered their phenotypic diversity in different cancers. The cancer metabolic environment has emerged as a critical modulator of myeloid cell functions in anti-tumor immunity versus immune suppression and immune evasion. Here, we discuss mechanisms of immune-metabolic crosstalk in tumorigenesis with a particular focus on tumor-associated myeloid cells metabolic programs. We highlight the impact of several metabolic pathways on the pro-tumoral functions of tumor-associated macrophages and myeloid-derived suppressor cells and discuss potential myeloid cell metabolic checkpoints for cancer immunotherapy either as monotherapies or in combination with other immunotherapies.

Title: PCSK9 in liver cancers at the crossroad between lipid metabolism and immunity
Authors: Malak Alannan1, Nabil G. Seidah2 and Aksam J. Merched1,
Affiliation: 1 Bordeaux University, 33000, Bordeaux, France: Inserm U 1312, Bordeaux Institute of Oncology, BRIC; 146 rue Léo Saignat, 33076 Bordeaux, France and 2 Laboratory of Biochemical Neuroendocrinology, Montreal Clinical Research Institute (IRCM, affiliated to the University of Montreal), Montreal, QC, H2W 1R7, Canada
Abstract: Metabolic rewiring and defective immune responses are considered as the main driving forces to sustain cell growth and oncogenesis in many cancers. The atypical enzyme, proprotein convertase subtilisin/kexin type 9 or PCSK9, is highly produced by the liver and plays a major role in lipid metabolism via the control of the LDL receptor and other cell surface receptors. In this context, many clinical studies clearly demonstrated the high efficacy of PCSK9 inhibitors in treating hyperlipidemia and cardiovascular diseases. Recent data implicated PCSK9 in the degradation of MHC-I receptors and the immune system as well as in other housekeeping activities. This review highlights the complex crosstalk between PCSK9, lipid metabolism and immunosuppression and underlines the latest advances in understanding the involvement of this enzyme in other critical functions. We present a comprehensive assessment of the different strategies targeting PCSK9 and show how these approaches could be extended to future therapeutic options to treat cancers with main focus

Back to TopTop